ESTRO 38 Abstract book

S885 ESTRO 38

interval. Primary endpoint was the symptom response rate. Results Forty patients (male/female: 29/11; median age: 84.0 years; range: 80-96) were included in the analysis. ECOG performance status was < 3 in 36 patients (90%). Patients with different cancer histology were included in the analysis, in particular: adenocarcinomas (N°=22; 55%), squamous cells (N°=15; 37.5%), small cell lung cancer (N°=3; 7%). With a median follow-up time of 1.2 months (range, 1 to 20 months), no G3 acute toxicities were observed, 2 (5%) G2 acute lung toxicity, 2 (5%) G1-G2 acute skin toxicities and 2 (5%) G1 esophagus toxicities were recorded. Among overall 26 symptomatic patients, 25 showed an improvement or resolution of baseline symptoms (overall palliative response rate: 96%). With a median survival time of 6 months, the median symptom free survival was 4 months. No differences in terms of quality of life was recorded after the treatment. Two of 40 (5%) patients required a retreatment that was performed in median after 5 months (range: 3-7 months) from the previous one. Conclusion Short-course accelerated radiotherapy in palliative setting of lung cancers is effective in terms of symptom relief and well tolerated even in elderly patients. EP-1644 Elderly patients with non-melanoma skin cancer:results of accelerated hypofractionated treatment M. Ferro 1 , G. Macchia 1 , E. Arena 1 , S. Cilla 2 , A. Ianiro 2 , V. Picardi 1 , M. Boccardi 1 , S. Cammelli 3 , A. Veraldi 3 , F. Bertini 3 , A. Arcelli 3 , M. Buwenge 3 , M.A. Sumon 4 , A. Kamal Uddin 4 , V. Valentini 5 , A.G. Morganti 3 , F. Deodato 1 , M. Ferro 1 1 Fondazione di Ricerca e Cura “Giovanni Paolo II”, Radiotherapy Unit, Campobasso, Italy ; 2 Fondazione di Ricerca e Cura “Giovanni Paolo II”, Medical Physics Unit, Campobasso, Italy ; 3 Radiation Oncology Center, Dept. of Experimental- Diagnostic and Specialty Medicine – DIMES- University of Bologna- S.Orsola-Malpighi Hospital, Bologna, Italy ; 4 United Hospital Limited, Radiation Oncology Department, Gulshan- Dhaka, Bangladesh ; 5 Policlinico Universitario “A. Gemelli”- Università Cattolica del Sacro Cuore, Department of Radiotherapy, Roma, Italy Purpose or Objective To assess the safety and efficacy of an accelerated radiotherapy schedule (Short Skin) in elderly patients with early stage non-melanoma skin cancer (NMSC). Material and Methods Eligibility criteria for the analysis were: 1) Patients with NMSC ≤ 3 cm, without infiltration of deep structures; 2) aged ≥80 years; 3) Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 3. Exclusion criteria were as follows: T3–T4 disease stage, prior RT on the same anatomical site, and poor compliance. Radiotherapy was delivered using electrons (6-9-12 MeV) or megavoltage photons (6MV) depending on tumor site and characteristics. The field size choice depended on the lesion size and location. For basal cell tumors of stage T1, the field size included a 1.5-cm normal tissue margin, while for stage T2 and/or squamous cell carcinomas, a 2.5– 3-cm margin was included. A total dose of 30 Gy was delivered in 5 Gy fractions throughout six consecutive days. Primary endpoint was the local control rate. Results Forty patients (male/female: 24/16; median age: 87.0 years; range: 80-98) were included in the analysis. ECOG performance status was < 3 in 37 patients (92,5%). The histology of skin cancer was squamous cell in 19 (47,5%) and basal cell in 19 (47,5%) patients, while 2 patients had mixed histology (5%). With a median follow-up time of 10 months (range, 2-63 months), no G3 acute skin toxicity

palliative treatment of H&N locally advanced or metastatic cancer in elderly patients. Material and Methods Eligibility criteria for the analysis were: 1) histological confirmed H&N cancers, 2) age ≥ 80 years, 3) expected survival > 3 months and 4) Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 3. A total dose of 20 Gy was delivered in 2 consecutive days with a twice daily fractionation (5 Gy per fraction) and at least 6-8 hour interval. Primary endpoint was the symptoms response rate. Results Thirty-four patients (male/female: 18/16; median age: 85.0 years; range: 80-98) were included in the analysis. ECOG performance status was < 3 in 17 patients (50%). Patients with different cancer types were included in the analysis, in particular the primary were: oral cavity (N°=13; 38.2%), larynx (N°=5; 14.7%), oropharynx (N°=4; 11.7%), salivary gland (N°=3; 8.8%), lip (N°=3; 8.8%), nasal cavity (N°=2; 5.8%), maxillary sinus (N°=3; 8.8%) and ethmoid sinus cancer (N°=1; 2.9%). With a median follow- up time of 4.5 months (range 1 to 28 months), two patients (5.9%) developed >/=G3 acute toxicities: one patient had a G3 mucositis and one had a G3 dysphagia requiring N-G feeding tube and G4 dyspnoea requiring tracheostomy. Moreover, 9 (26.4%) G1-G2 acute pharyngeal toxicities, 8 (23.5 %) G1-G2 acute skin toxicities and 9 (26.4 %) G1-2 mucositis were recorded. Overall palliative response rate was 76.5%. Moreover, among 24 symptomatic patients for pain, 21 showed an improvement or resolution with an overall pain response rate of 87%. No detrimental effects in terms of quality of life (CLAS 1,2,3) were observed after the treatment. The median survival time was 9 months, with a median palliative progression free survival of 8 months. Conclusion Short-course accelerated radiotherapy in palliative setting of Head & Neck cancers is effective in terms of symptom relief and well tolerated even in elderly patients. EP-1643 Short-course accelerated palliative radiotherapy for advanced lung cancer in elderly patients M. Ferro 1 , M. Ferro 1 , F. Deodato 1 , S. Cilla 2 , A. Ianiro 2 , V. Picardi 1 , M. Boccardi 1 , E. Arena 1 , S. Cammelli 3 , M. Ferioli 3 , A. Zamagni 3 , S. Bisello 3 , E. Farina 3,4 , M. Buwenge 3 , P. Assalone 5 , A.A. Woldemariam 6 , T. Wondemagegnhu 6 , V. Valentini 7 , A.G. Morganti 3 , G. Macchia 1 1 Fondazione di Ricerca e Cura “Giovanni Paolo II”, Radiotherapy Unit, Campobasso, Italy ; 2 Fondazione di Ricerca e Cura “Giovanni Paolo II”, Medical Physics Unit, Campobasso, Italy ; 3 Radiation Oncology Center, Dept. of Experimental- Diagnostic and Specialty Medicine – DIMES- S.Orsola-Malpighi Hospital, Bologna, Italy ; 4 Maria Cecilia Hospital- GVM Care & Research, Radiation Oncology Unit, Cotignola RA, Italy ; 5 Veneziale Hospital, Oncology Unit, Isernia, Italy ; 6 Black Lion Hospital, Department of Radiotherapy, Addis-Ababa, Ethiopia ; 7 Policlinico Universitario “A. Gemelli”- Università Cattolica del Sacro Cuore, Department of Radiotherapy, Roma, Italy Purpose or Objective To assess the safety and efficacy of a SHort-course Accelerated RadiatiON therapy (SHARON) regimen in the palliative treatment of locally advanced or metastatic lung cancer in elderly patients. Material and Methods Eligibility criteria for the analysis were: 1) histological confirmed lung cancers, 2) age ≥ 80 years, 3) expected survival > 3 months and 4) Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 3. A total dose of 20 Gy was delivered in 2 consecutive days with a twice daily fractionation (5 Gy per fraction) and at least 8 hour